Immunicum AB (publ) (IMMU.ST)
- Globe Newswire
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001After a median follow-up period of 14.3 months, median relapse-free survival (RFS) and overall survival (OS) have not yet been reachedThe estimated 6-month RFS based on the currently available data is 83.7% and the estimated 6-mon
- Globe Newswire
Immunicum AB: Report from the Annual General Meeting of Immunicum AB (publ) on 10 May 2022
At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 10 May 2022 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.immunicum.com. Adoption of the balance sheet and income statement, disposition regarding the Company’
- Globe Newswire
Immunicum AB: Immunicum AB (publ) Interim Report January – March 2022
JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (–).Result for the period amounted to KSEK -27,582 (-41,571).Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).Immunicum transfers patent rights for modified adenovirus to Elicera TherapeuticsImmunicum provided a pipeline and strategy outlook. In 2022, the clinical development focus will be on i) the continuation and further clinical data updates of the ADVANCE II study evaluating DCP-001 in the acute myel
